_version_ 1785119716568727552
author Chiricozzi, Andrea
Ortoncelli, Michela
Schena, Donatella
Gori, Niccolò
Ferrucci, Silvia Mariel
Babino, Graziella
Napolitano, Maddalena
Fargnoli, Maria Concetta
Stingeni, Luca
Rossi, Mariateresa
Romanelli, Marco
Balestri, Riccardo
Pellegrino, Michele
Parodi, Aurora
Bertoldi, Alberto Maria
Palazzo, Giovanni
Antonelli, Flaminia
Pitino, Annalisa
Tripepi, Giovanni
Fabbrocini, Gabriella
Balato, Anna
Marzano, Angelo Valerio
Girolomoni, Giampiero
Ribero, Simone
Peris, Ketty
author_facet Chiricozzi, Andrea
Ortoncelli, Michela
Schena, Donatella
Gori, Niccolò
Ferrucci, Silvia Mariel
Babino, Graziella
Napolitano, Maddalena
Fargnoli, Maria Concetta
Stingeni, Luca
Rossi, Mariateresa
Romanelli, Marco
Balestri, Riccardo
Pellegrino, Michele
Parodi, Aurora
Bertoldi, Alberto Maria
Palazzo, Giovanni
Antonelli, Flaminia
Pitino, Annalisa
Tripepi, Giovanni
Fabbrocini, Gabriella
Balato, Anna
Marzano, Angelo Valerio
Girolomoni, Giampiero
Ribero, Simone
Peris, Ketty
author_sort Chiricozzi, Andrea
collection PubMed
description
format Online
Article
Text
id pubmed-10570227
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-105702272023-10-14 Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation Chiricozzi, Andrea Ortoncelli, Michela Schena, Donatella Gori, Niccolò Ferrucci, Silvia Mariel Babino, Graziella Napolitano, Maddalena Fargnoli, Maria Concetta Stingeni, Luca Rossi, Mariateresa Romanelli, Marco Balestri, Riccardo Pellegrino, Michele Parodi, Aurora Bertoldi, Alberto Maria Palazzo, Giovanni Antonelli, Flaminia Pitino, Annalisa Tripepi, Giovanni Fabbrocini, Gabriella Balato, Anna Marzano, Angelo Valerio Girolomoni, Giampiero Ribero, Simone Peris, Ketty Am J Clin Dermatol Correction Springer International Publishing 2023-08-19 2023 /pmc/articles/PMC10570227/ /pubmed/37597128 http://dx.doi.org/10.1007/s40257-023-00813-4 Text en © Springer Nature Switzerland AG 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Correction
Chiricozzi, Andrea
Ortoncelli, Michela
Schena, Donatella
Gori, Niccolò
Ferrucci, Silvia Mariel
Babino, Graziella
Napolitano, Maddalena
Fargnoli, Maria Concetta
Stingeni, Luca
Rossi, Mariateresa
Romanelli, Marco
Balestri, Riccardo
Pellegrino, Michele
Parodi, Aurora
Bertoldi, Alberto Maria
Palazzo, Giovanni
Antonelli, Flaminia
Pitino, Annalisa
Tripepi, Giovanni
Fabbrocini, Gabriella
Balato, Anna
Marzano, Angelo Valerio
Girolomoni, Giampiero
Ribero, Simone
Peris, Ketty
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
title Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
title_full Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
title_fullStr Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
title_full_unstemmed Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
title_short Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
title_sort correction to: long-term effectiveness and safety of upadacitinib for atopic dermatitis in a real-world setting: an interim analysis through 48 weeks of observation
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570227/
https://www.ncbi.nlm.nih.gov/pubmed/37597128
http://dx.doi.org/10.1007/s40257-023-00813-4
work_keys_str_mv AT chiricozziandrea correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT ortoncellimichela correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT schenadonatella correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT goriniccolo correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT ferruccisilviamariel correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT babinograziella correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT napolitanomaddalena correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT fargnolimariaconcetta correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT stingeniluca correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT rossimariateresa correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT romanellimarco correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT balestririccardo correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT pellegrinomichele correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT parodiaurora correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT bertoldialbertomaria correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT palazzogiovanni correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT antonelliflaminia correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT pitinoannalisa correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT tripepigiovanni correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT fabbrocinigabriella correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT balatoanna correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT marzanoangelovalerio correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT girolomonigiampiero correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT riberosimone correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation
AT perisketty correctiontolongtermeffectivenessandsafetyofupadacitinibforatopicdermatitisinarealworldsettinganinterimanalysisthrough48weeksofobservation